JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257627

Human RANBP2 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

RANBP2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 211 bp insertion in exon1 and 82 bp insertion in exon1.
3 Images
Western blot - Human RANBP2 knockout HeLa cell lysate (AB257627)
  • WB

Lab

Western blot - Human RANBP2 knockout HeLa cell lysate (AB257627)

Lane 1 : Wild-type HeLa cell lysate 20 μg
Lane 2 : RANBP2 knockout HeLa cell lysate 20 μg
Lane 3 : Caco2 cell lysate 20 μg
Lane 4 : MCF7 cell lysate 20 μg

Lanes 1 - 4 : Merged signal (red and green). Green - ab64276 observed at 450 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55 kDa.

ab64276 was shown to react with RanBP2 in wild-type HeLa cells in Western blot with loss of signal observed in RANBP2 knockout cell line ab265618 (RANBP2 knockout cell lysate ab257627). Wild-type HeLa and RANBP2 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab64276 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 : 1000 dilution and 1 : 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 : 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-RanBP2 antibody (<a href='/en-us/products/primary-antibodies/ranbp2-antibody-ab64276'>ab64276</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

RANBP2 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human RANBP2 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-ranbp2-knockout-hela-cell-line-ab265618'>ab265618</a>)

Lane 3:

Caco2 cell lysate at 20 µg

Lane 4:

MCF7 cell lysate at 20 µg

Predicted band size: 358 kDa

Observed band size: 450 kDa

false

Sanger Sequencing - Human RANBP2 knockout HeLa cell lysate (AB257627)
  • Sanger seq

Unknown

Sanger Sequencing - Human RANBP2 knockout HeLa cell lysate (AB257627)

Allele-1 : 82 bp insertion in exon1

Sanger Sequencing - Human RANBP2 knockout HeLa cell lysate (AB257627)
  • Sanger seq

Unknown

Sanger Sequencing - Human RANBP2 knockout HeLa cell lysate (AB257627)

Allele-2 : 211 bp insertion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 211 bp insertion in exon1 and 82 bp insertion in exon1.

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257627-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human RANBP2 knockout HeLa cell lysate", "number":"AB257627-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257627-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
RANBP2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RanBP2 also known as Nucleoporin 358 (Nup358) is a large protein with a molecular mass of approximately 358 kDa. It is an important component of the nuclear pore complex (NPC) and is found on the cytoplasmic side of the nuclear envelope. RanBP2 is expressed in a variety of tissues with higher levels in the brain and testis. Its alternates names include Nup358 due to its role as a nucleoporin. Mechanically RanBP2 facilitates nucleocytoplasmic transport by interacting with the small GTPase Ran.
Biological function summary

RanBP2 plays a significant role in multiple processes such as mitotic spindle assembly and chromatin condensation. It functions as part of the Ran GTPase system a critical complex for nucleocytoplasmic transport. In addition RanBP2 contributes to protein sumoylation where it acts as a scaffold for conjugating enzymes. It maintains nuclear envelope integrity and supports the positioning of centrosomes during cell division.

Pathways

RanBP2 is actively involved in the nucleocytoplasmic transport pathway ensuring the proper exchange of proteins and RNA between the nucleus and cytoplasm. It is critical to the Ran cycle where it works alongside proteins like RanGTP and RanGAP1 to regulate transport activities. The involvement of RanBP2 in the SUMOylation pathway also emphasizes its role in post-translational modification impacting various cellular events and signaling.

Changes in RanBP2 expression have been linked to neurodegenerative diseases and certain types of cancer. In neurodegenerative conditions such as hereditary spastic paraplegia RanBP2 forms a complex with proteins like atlastin-1 which further influences disease progression. In cancer RanBP2 interacts with oncogenic pathways through its role in cell cycle regulation highlighting its potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com